Pfizer Received Positive EU’S CHMP Opinion for Elrexfio to Treat Multiple Myeloma
Shots:
- The CHMP's positive opinion was based on Cohort A of P-II (MagnetisMM-3) evaluating Elrexfio for r/r Multiple Myeloma patients
- The P-II study results depicted OR of 61% & 72% chance of maintaining response at 15 mos., furthermore, after switching to Q2W dosage at least 6 mos. before the data cut-off date (n = 50), 38% of responding patients had a complete response (CR), and 80% of patients maintained or improved their response
- Elrexfio is a subcutaneously administered immunotherapy that combines B-cell maturation antigen (BCMA)-CD3-directed BsAbs to kill myeloma cells by binding to BCMA on the cells and CD3 on the T-cells.
Ref: Pfizer | Image: Pfizer
Related News:- Pfizer’s Elrexfio Receives the US FDA’s Accelerated Approval for Relapsed or Refractory Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
